Clinical Trials in Myeloproliferative Neoplasms (MPN)

 

Trial Name

 

Trial Summary

 

Hyperlink

 

MANIFEST

 

A phase 2 study looking at the addition of a BET-inhibitor (CPI-0610), for patients with myelofibrosis, including those that have taken ruxolitinib.

 

KRT-102

 This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with phlebotomy-dependent polycythemia vera (PV).